Abstract: The invention provides new derivatives of vitamin D.sub.3 and specifically (22E,24R)-1,24-dihydroxy-.DELTA..sup.22 -vitamin D.sub.3 and (22E,24S)-1,24-dihdroxy-.DELTA..sup.22 -vitamin D.sub.3.The compounds exhibit vitamin D-like activity in their ability to stimulate intestinal calcium transport, increase serum inorganic phosphorous and mineralize bone indication ready application of the compounds in the treatment of various metabolic bone diseases. The characteristic of the compounds to not mobilize bone indicates that the compositions would find ready application in combination with vitamin D and various of its derivatives to achieve controlled bone mineralization.

Abstract: The invention provides new derivatives of vitamin D, 23,23-difluoro-25-hydroxycholecalciferol and the acylates thereof, a method for preparing said compounds and various new intermediates utilized in such process.The derivative compounds are characterized by vitamin D-like activity as evidenced by their ability to increase intestinal calcium transport and serum calcium. The compounds are further characterized by resistance to hydroxylation at C-23, which is recognized as an essential metabolic step to the inactivation of vitamin D. The compounds should, therefore, provide vitamin D-like activity of greater time duration.

Abstract: The invention provides new derivatives of vitamin D, 23,23-difluoro-1,25-dihydroxycholecalciferol and the acylates thereof.The derivative compounds are characterized by vitamin D-like activity.

Abstract: The invention provides a new derivative of vitamin D, 23,23-difluoro-1,25-dihydroxycholecalciferol.The compound is characterized by vitamin D-like activity as evidenced by its ability to increase intestinal calcium transport. It is further characterized by its resistance to hydroxylation at C-23, which is recognized as an essential metabolic step to the inactivation of vitamin D, and therefore should provide vitamin D-like activity of greater time duration.

Abstract: The invention provides a new derivative of vitamin D, 23,23-difluoro-25-hydroxycholecalciferol, a method for preparing said compound and various new intermediates utilized in such process.The compound is characterized by vitamin D-like activity as evidenced by its ability to increase intestinal calcium transport and serum calcium. It is further characterized by its resistance to hydroxylation at C-23, which is recognized as an essential metabolic step to the inactivation of vitamin D, and therefore should provide vitamin D-like activity of greater time duration.

Abstract: This invention provides a new method for preparing 26,26,26,27,27,27-hexafluoro-1,25-dihydroxycholesterol.The method permits the use of cholenic acid or an ester of cholenic acid as the starting material and the preparation of a compound which can be readily converted into a highly active derivative of vitamin D, 26,26,26,27,27,27-hexafluoro-1.alpha.,25-dihydroxycholecalciferol.

Abstract: This invention provides a new derivative of vitamin D, 26,26,26,27,27,27-hexafluoro-1.alpha.,25-dihydroxycholecalciferol, a process for preparing the same, and novel intermediate compounds.The compound is characterized by vitamin D-like activity substantially greater than that exhibited by 1.alpha.,25-dihydroxycholecalciferol which is considered to be the active hormonal form of vitamin D. The compound would find ready application as a substitute for vitamin D and in the treatment of or prophylaxis for disease states evincing metabolic calcium and phosphorous deficiences or imbalances.

Abstract: The invention provides new derivatives of vitamin D.sub.3, specifically, 1.alpha.,25-dihydroxy-2.beta.-fluorocholecalciferol.The compound is characterized by vitamin D-like activity as measured by its ability to stimulate intestinal calcium transport, mobilization of calcium from bone, increase serum inorganic phosphorous and in their antirachitic activity. The compound, could, therefore, find ready application as a substitute for vitamin D in its various known applications and in the treatment of various metabolic bone diseases.

Abstract: The invention provides a new derivative of vitamin D.sub.3, 24-fluoro-25-hydroxycholecalciferol.The compound is characterized by vitamin D-like activity in its ability to increase intestinal calcium transport, increase serum calcium and inorganic phosphorous concentration and to prevent the development of rickets. It would find ready application as a substitute for vitamin D.sub.3 and in the treatment of disease states evincing calcium-phosphorous imbalance and which are nonresponsive to vitamin D.sub.3 therapy.

Abstract: The invention provides new derivatives of vitamin D.sub.3, specifically, 1.alpha.-hydroxy-2.beta.-fluorocholecalciferol.The compound is characterized by vitamin D-like activity as measured by its ability to stimulate intestinal calcium transport, mobilize calcium from bone, increase serum inorganic phosphorous and in their antirachitic acitivity. The compound could, therefore, find ready application as a substitute for vitamin D in its various known applications and in the treatment of various metabolic bone diseases.

Abstract: The invention provides a new derivative of vitamin D, 25-hydroxy-26,26,26,27,27,27-hexafluorocholecalciferol and a process for preparing the same.The compound is characterized by vitamin D-like activity in their ability to increase intestinal calcium transport, increase serum calcium and to prevent the development of rickets. These compounds would find ready application as a substitute for vitamin D and in the treatment of disease states evincing metabolic calcium and phosphorus deficiencies.

Abstract: The invention provides new derivatives of vitamin D, 24,24-difluoro-1.alpha.,25-dihydroxycholecalciferol and 24,24-difluoro-1.alpha.,25-dihydroxy-5,6-trans-cholecalciferol and processes for preparing the same.The compounds are characterized by vitamin D-like activity essentially equivalent to the vitamin D-like activity of 1.alpha.,25-dihydrocholecalciferol which is considered to be the hormonal form and most active derivative of vitamin D. The compounds of this invention are characterized by their ability to increase intestinal calcium transport, increase serum calcium and to prevent the development of rickets. These compounds would find ready application as a substitute for vitamin D and in the treatment of disease states evincing metabolic calcium and phosphorus deficiences.

Abstract: The invention provides new derivatives of vitamin D, 24,24-difluoro-1.alpha.,25-dihydroxycholecalciferol and 24,24-difluoro-1.alpha.,25-dihydroxy-5,6-trans-cholecalciferol and processes for preparing the same.The compounds are characterized by vitamin D-like activity essentially equivalent to the vitamin D-like activity of 1.alpha.,25-dihydrocholecalciferol which is considered to be the hormonal form and most active derivative of vitamin D. The compounds of this invention are characterized by their ability to increase intestinal calcium transport, increase serum calcium and to prevent the development of rickets. These compounds would find ready application as a substitute for vitamin D and in the treatment of disease states evincing metabolic calcium and phosphorus deficiencies.

Abstract: The invention provides a new derivative of vitamin D.sub.3, 24,24-difluoro-25-hydroxycholecalciferol.The compound is characterized by vitamin D-like activity in its ability to increase intestinal calcium transport, increase serum calcium and inorganic phosphorous concentration and to prevent the development of rickets. It would find ready application as a substitute for vitamin D.sub.3 and in the treatment of disease states evincing calcium-phosphorous imbalance and which are non-responsive to vitamin D.sub.3 therapy.

Abstract: Novel 1.alpha., 24-dihydroxycholecalciferol and derivatives thereof which are useful with reduced side-effects for the treatment of abnormal metabolism of calcium and phosphorus caused by liver failure, renal failure, gastrointestinal tract failure and parathyroid failure, and related bone diseases. Preparation of the novel 1.alpha., 24-dihydroxycholecalciferol and their derivatives starts from 1.alpha., 24-dihydroxycholesterol prepared by reacting 1.alpha., 2.alpha.-epoxy-24-keto-cholesta-4,6-dien-3-one with an alkali metal and a proton donor in the presence of liquid ammonia or a liquid amine. Reaction of the 1.alpha., 24-dihydroxycholesterol with an allylic brominating agent, followed by contacting with a dehydrobrominating agent, affords 1.alpha.,3.beta., 24-trihydroxycholesta-5,7-diene derivative, which can then be converted to 1.alpha., 24-dihydroxycholocalciferol by ultraviolet irradiation in a organic solvent, followed by isomerization. Processes are also provided for separating 1.alpha.